Folia Health joins the Cancer Moonshot’s CancerX Public-Private Partnership as a Founding Member
02 juin 2023 08h00 HE
|
Folia Health
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Folia Health, a health technology company and a leader in patient-centered outcomes research, has announced today its participation in CancerX's inaugural...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
01 juin 2023 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
atai Life Sciences to Participate in Upcoming June Investor Conferences
01 juin 2023 06h59 HE
|
atai Life Sciences
NEW YORK and BERLIN, June 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference
31 mai 2023 08h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...
Global Radiation Therapy Market Report 2023: Surface-Guided Radiotherapy Boosts Sector
30 mai 2023 09h48 HE
|
Research and Markets
Dublin, May 30, 2023 (GLOBE NEWSWIRE) -- The "Global Radiation Therapy Market with Focus on LINAC: Insights & Forecast with Potential Impact of COVID-19 (2023-2027)" report has been added to ...
PHARMANOVIA ENTERS NEW CHEMICAL ENTITY LICENSING AGREEMENT WITH STEALTH BIOTHERAPEUTICS TO MARKET AND FURTHER DEVELOP A POTENTIAL NOVEL TREATMENT FOR BARTH SYNDROME
30 mai 2023 09h25 HE
|
Pharmanovia
Basildon, UK, May 30, 2023 (GLOBE NEWSWIRE) -- PRESS RELEASE - FOR BUSINESS & TRADE MEDIA ONLY THE AGREEMENT COVERS RIGHTS FOR ELAMIPRETIDE FOR BARTH SYNDROME IN THE EU, NORWAY, SWITZERLAND,...
Global Omega 3 Prescription Drugs Market Report 2023: Rising Cases of Cardiovascular Disease Drives Growth
30 mai 2023 07h53 HE
|
Research and Markets
Dublin, May 30, 2023 (GLOBE NEWSWIRE) -- The "Omega 3 Prescription Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
Technology Advances in Senolytics 2023: Innovative Drug Development Culture Working to Prolong Health Spans and Eliminate Aging Cells
26 mai 2023 05h53 HE
|
Research and Markets
Dublin, May 26, 2023 (GLOBE NEWSWIRE) -- The "Technology Advances in Senolytics" report has been added to ResearchAndMarkets.com's offering. Senolytics is a relatively new field of development...
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
25 mai 2023 17h00 HE
|
Regeneron Pharmaceuticals, Inc.
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-PD-1 alone in similar...
Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st
25 mai 2023 08h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone...